Claus-Henning Köhne

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine · 2009 · 3.9K citations · Full text

Medicine, Oncology, Pharmacology +17

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status

Eric Van Cutsem, Claus-Henning Köhne, István Láng et al. · Journal of Clinical Oncology · 2011 · 1.9K citations · Full text

Medicine, Oncology, Pharmacology +17

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Eric Van Cutsem, Heinz‐Josef Lenz, Claus-Henning Köhne et al. · Journal of Clinical Oncology · 2015 · 800 citations · Full text

Medicine, Oncology, Pharmacology +17

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Aron Goldhirsch, Richard D. Gelber, Martine Piccart et al. · The Lancet · 2013 · 501 citations

Medicine, Oncology, Breast Oncology +13

Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma

Eric Van Cutsem, Emilio Bajetta, Juan W. Valle et al. · Journal of Clinical Oncology · 2011 · 162 citations

Medicine, Oncology, Pharmacology +11